Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41)

British Medical Journal

Volumn 320, Issue 7246, 2000, Pages 1373-1378

  Gray, Alastair ^a   Turner, Robert ^d   Raikou, Maria ^b   McGuire, Alistair ^b   Fenn, Paul ^c   Stevens, Richard ^d   Cull, Carole ^d   Stratton, Irene ^d   Adler, Amanda ^d   Holman, Rury ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

^c NOTTINGHAM UNIVERSITY BUSINESS SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

EID: 0034690657     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.320.7246.1373     Document Type: Article

References (12)

1. 1 The Diabetes Control and Complications Trial Research Group (DCCT). Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409-15.
2. 2 Buxton M, Sculpher M, Ferguson B, Humphreys JE, Altman JF, Spiegelhalter DJ, et al. Screening for treatable diabetic retinopathy: a comparison of different methods. Diabetic Med 1991;8:371-7.
3. 3 Sculpher M, Buxton M, Ferguson B, Spiegelhalter D, Kirby A. Screening for diabetic retinopathy: a relative cost-effectiveness analysis of alternative modalities and strategies. Health Economics 1992;1:39-52.
4. 4 Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model of construction and assumptions. Diabetes Care 1997;20:725-34.
5. 5 Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley MC, Maier W, et al. Model of complications of NIDDM. 2. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44.
6. 6 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
7. 7 Netten A, Dennett J. Unit cost of community care. Canterbury: Personal Social Services Research Unit, University of Kent, 1998.
8. 8 Treasury, Appraisal and evalution in central government. London, Stationery Office, 1997.
9. 9 Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics 1996;5:297-305.
10. 10 Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996;15:1447-58.
11. 11 Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs effects and c/e-ratios alongside a clinical trial. Health Economics 1994;3:309-19.
12. 12 UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-36.